Kronos Bio Valuation
| KRONDelisted Stock | USD 0.88 0.00 0.00% |
Today, the firm appears to be overvalued. Kronos Bio secures a last-minute Real Value of $0.71 per share. The latest price of the firm is $0.88. Our model forecasts the value of Kronos Bio from analyzing the firm fundamentals such as Operating Margin of (3.42) %, shares outstanding of 60.97 M, and Return On Equity of -0.59 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kronos Bio's price fluctuation is very steady at this time. Calculation of the real value of Kronos Bio is based on 3 months time horizon. Increasing Kronos Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kronos Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kronos Stock. However, Kronos Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.88 | Real 0.71 | Hype 0.88 | Naive 0.82 |
The intrinsic value of Kronos Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Kronos Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Kronos Bio helps investors to forecast how Kronos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kronos Bio more accurately as focusing exclusively on Kronos Bio's fundamentals will not take into account other important factors: About Kronos Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Kronos Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Kronos Bio based exclusively on its fundamental and basic technical indicators. By analyzing Kronos Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Kronos Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kronos Bio. We calculate exposure to Kronos Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kronos Bio's related companies.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company was incorporated in 2017 and is headquartered in San Mateo, California. Kronos Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Kronos Stock
If you are still planning to invest in Kronos Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kronos Bio's history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |